Photocure ASA: New analysis shows Hexvix®/Cysview® significantly prolongs time to progression of bladder cancer
Photocure ASA Oslo, Norway, 26[th] April 2016: Photocure ASA (OSE: PHO), is pleased to announce publication of a new analysis demonstrating that Blue Light Cystoscopy (BLC) with Hexvix/Cysview significantly prolonged time to disease progression and showed a trend in the reduction of the rate of progression in patients with non-muscle invasive bladder cancer (NMIBC). The data was published online in the April issue of the peer reviewed journal, Bladder Cancer http://content.iospress.com/articles/bladder-cancer/blc160048. The new analysis of a long term follow-up study classified patients